Author(s): Zhou J; Wearn A; Huck J; Hughes CS; Baracchini G; Sylvain E; Tremblay-Mercier J; Poirier J; Breitner JCSCS; Villeneuve S; Chakravarty MM; Tardif CL; Gauthier CJ; Daugherty AM; Turner GR; Spreng RN;

Background: Elevated brain iron deposition is recognized as a characteristic of normal aging and neurodegenerative diseases, particularly Alzheimer's disease (AD), where it correlated with amyloid-ß plaques and neurofibrillary tangles. Our study aimed to investigate the relationship between l ...

Article GUID: 41499788

Author(s): Cunningham NP; Tremblay-Mercier J; Baril AA; Dang-Vu TT; Lim A; Geddes MR; Badawy M; Poirier J; Ducharme S; Villeneuve S;

Background: Poor sleep is a modifiable factor associated with the development and progression of Alzheimer's Disease (AD). Pharmacological treatments and Cognitive Behavioural Therapy for Insomnia (CBT-I) which promote sleep have the potential to improve AD risk profile. In addition, prior re ...

Article GUID: 41450269

Author(s): Villeneuve S; Poirier J; Breitner JCS; Tremblay-Mercier J; Remz J; Raoult JM; Yakoub Y; Gallego-Rudolf J; Qiu T; Fajardo Valdez A; Mohammediyan B; Javanray M; Metz A; Sanami S; Ourry V; Wearn A; Pastor-Bernier A; Edde M; Gonneaud J; Stri ...

The PResymptomatic EValuation of Experimental or Novel Treatments for Alzheimer's Disease (PREVENT-AD) is an investigator-driven study that was created in 2011 and enrolled cognitively normal older adults with a family history of sporadic AD. Participants are deeply phenotyped and have now be ...

Article GUID: 41020412

Author(s): Villeneuve S; Poirier J; Breitner JCS; Tremblay-Mercier J; Remz J; Raoult JM; Yakoub Y; Gallego-Rudolf J; Qiu T; Valdez AF; Mohammediyan B; Javanray M; Metz A; Sanami S; Ourry V; Wearn A; Pastor-Bernier A; Edde M; Gonneaud J; Strikwerda- ...

The PREVENT-AD is an investigator-driven study that was created in 2011 and enrolled cognitively normal older adults with a family history of sporadic AD. Participants are deeply phenotyped and have now been followed annually for more than 12 years [median follow-up 8.0 years,SD 3.1]. Multimodal ...

Article GUID: 40778177

Author(s): Wearn A; Tremblay SA; Tardif CL; Leppert IR; Gauthier CJ; Baracchini G; Hughes C; Hewan P; Tremblay-Mercier J; Rosa-Neto P; Poirier J; Villeneuve S; Schmitz TW; Turner GR; Spreng RN;

The neuromodulatory subcortical nuclei within the isodendritic core (IdC) are the earliest sites of tauopathy in Alzheimer's disease (AD). They project broadly throughout the brain's white matter. We investigated the relationship between IdC microstructure and whole-brain white matter mic ...

Article GUID: 38830849

Author(s): Zhou J; Wearn A; Huck J; Hughes C; Baracchini G; Tremblay-Mercier J; Poirier J; Villeneuve S; Tardif CL; Chakravarty MM; Daugherty AM; Gauthier CJ; Turner GR; Spreng RN;

Elevated iron deposition in the brain has been observed in older adult humans and persons with Alzheimer's disease (AD), and has been associated with lower cognitive performance. We investigated the impact of iron deposition, and its topographical distribution across hippocampal subfields and ...

Article GUID: 38388425

Author(s): Poline JB; Das S; Glatard T; Madjar C; Dickie EW; Lecours X; Beaudry T; Beck N; Behan B; Brown ST; Bujold D; Beauvais M; Caron B; Czech C; Dharsee M; Dugré M; Evans K; Gee T; Ippoliti G; Kiar G; Knoppers BM; Kuehn T; Le D; Lo D; Mazaheri ...

We present the Canadian Open Neuroscience Platform (CONP) portal to answer the research community's need for flexible data sharing resources and provide advanced tools for search and processing infrastructure capacity. This portal differs from previous data sharing projects as it integrates d ...

Article GUID: 37024500